**Novo Nordisk 'B' NON.DK** | COPENHAGEN Exch | Medical-Diversified | MktCap DKK2.14T Sales DKK290.40B | Shares 3.390B Float 3.390B | EPS Due in 62 Days (e)

4544448888 novonordisk.com Bagsværd, DENMARK Inc 1931 MGMT owns --

EPS Rank 91

Novo Nordisk A S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark. LESS

| ANNUAL - DEC END | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|
| EPS DKK | 7.50 | 7.71 | 7.98 | 8.20 | 9.03 | 10.40 | 12.26 | 18.67 | 22.67 |
| CASH FLOW/SHR DKK | 9.54 | 8.31 | 9.21 | 9.84 | 11.10 | 11.94 | 17.36 | 24.23 | 27.10 |
| PRETAX MARGIN % | 43% | 44% | 43% | 40% | 42% | 42% | 39% | 45% | 44% |
| RETURN ON EQUITY % | 82% | 80% | 76% | 71% | 70% | 71% | 72% | 88% | 81% |
| SALES % CHANGE | 4% | 0% | 0% | 9% | 4% | 11% | 26% | 31% | 25% |
| SALES (MIL) DKK | 112K | 112K | 112K | 122K | 127K | 141K | 177K | 232K | 290K |

| WEEKLY | Jan 10 | Jan 17 | Jan 24 | Jan 31 | Feb 7 | Feb 14 | Feb 21 | Feb 28 | Mar 5 |
|---|---|---|---|---|---|---|---|---|---|
| DATAGRAPH RATING | 30 | 31 | 32 | 30 | 32 | 32 | 33 | 33 | 32 |
| AVG DAILY VOL (000) | 3,974 | 4,003 | 4,152 | 4,090 | 4,285 | 4,408 | 4,583 | 4,805 | 4,798 |
| UP DOWN VOLUME | 0.9 | 0.8 | 0.9 | 0.9 | 0.8 | 0.7 | 0.8 | 0.9 | 0.8 |
| ACCUM/DIST RATING | -6 | -22 | 12 | 14 | 26 | -5 | 19 | 29 | 28 |
| RELATIVE STRENGTH | 14 | 10 | 15 | 12 | 14 | 10 | 14 | 14 | 13 |
| GROUP RANK | 54 | 58 | 54 | 53 | 53 | 57 | 54 | 55 | 55 |

| 2025 Estimate | 2026 Estimate |
|---|---|
| 27.41 21% | |

| Earnings Growth Rate | Sales Growth Rate |
|---|---|
| 2022-24 33% (4 Stability) | 28% |
| 2020-24 24% (8 Stability) | 20% |

COMP RATING 65 SMR RATING A

INV T/O 1.3x 45

| | | | | |
|---|---|---|---|---|
| DEBT % | 2022-24 | 29% | 19% | 63% |
| TAX RATE | 2022-24 | 20% | 20% | 21% |
| BACKLOG | 2022-24 | -- | -- | -- |

R & D 13.10% BK VAL 19.55x '24

DIV DKK 11.40 (1.8%) DIV GR RT+23% (9)

BETA 1.46(96.00) ALPHA 0.00 (0.00)

2024 EMPLOYEES 76,302 (20%)







| FINANCIALS | Mar 21 | Jun 21 | Sep 21 | Dec 21 | Mar 22 | Jun 22 | Sep 22 | Dec 22 | Mar 23 | Jun 23 | Sep 23 | Dec 23 | Mar 24 | Jun 24 | Sep 24 | Dec 24 | Mar 25 | Jun 25 | Sep 25 | Dec 25 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| EPS (DKK) | 2.73 | 2.63 | 2.64 | 2.38 | 3.12 | 2.93 | 3.18 | 3.02 | 4.40 | 4.33 | 5.02 | 4.92 | 5.70 | 4.50 | 6.13 | 6.35 | 6.35e | 6.52e | 7.38e | 7.40e |
| EPS % CHANGE | +8% | +16% | +19% | +18% | +14% | +11% | +20% | +27% | +41% | +48% | +58% | +63% | +30% | +4% | +22% | +29% | +11%e | +45%e | +20%e | +17%e |
| SALES (MIL DKK) | 33,804.0 | 33,041.0 | 35,622.0 | 38,333.0 | 42,031.0 | 41,265.0 | 45,566.0 | 48,092.0 | 53,367.0 | 54,300.0 | 58,731.0 | 65,863.0 | 65,349.0 | 68,060.0 | 71,311.0 | 85,683.0 | 81,949.9e | 84,801.2e | 89,077.5e | 97,769.8e |
| SALES % CHANGE | 0% | +10% | +15% | +19% | +24% | +25% | +28% | +25% | +27% | +32% | +29% | +37% | +22% | +25% | +21% | +30% | +25%e | +25%e | +25%e | +14%e |
| EPS % SURPRISE | +8.7% | +7.3% | +5.8% | +1.3% | +6.4% | -1.7% | +2.9% | +3.4% | +3.9% | -5.8% | +4.0% | +7.3% | +8.7% | -7.6% | +2.0% | +6.1% | | | | |
| FUNDS | 3,123 | 3,210 | 3,337 | 3,570 | 3,572 | 3,841 | 3,922 | 4,103 | 4,250 | 4,499 | 4,725 | 4,978 | 5,218 | 5,447 | 5,432 | 5,364 | | | | |
| SHARES HELD BY FUNDS | 1B | 1B | 1B | 1B | 1B | 1B | 1B | 1B | 1B | 1B | 1B | 1B | 1B | 1B | 1B | 1B | | | | |

| P/E | 28 |
|---|---|
| 2025 Est.: | 23.0 |
| 2026 Est.: | |
| 5-yr High: | 51 |
| 5-yr Low: | 19 |
| vs Ind. Avg: | 0.8x |

PANARAY® 2025 WILLIAM O'NEIL + CO. INC.